| Therese Bartholomew Bevers, M.D., F.A.A.F.P. |
Present Title & Affiliation
Primary Appointment
Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Cancer Prevention Center, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Prevention Outreach Programs, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Bio Statement
Dr. Therese B. Bevers is professor of Clinical Cancer Prevention and the medical director of the
Her clinical and research interests are in the area of breast cancer prevention, screening, diagnosis and survivorship. She was an investigator on the groundbreaking Breast Cancer Prevention Trial which demonstrated that tamoxifen reduced the risk of developing breast cancer by one half and currently serves as the institutional principal investigator (PI) for the STAR trial which showed that raloxifene had similar benefits but fewer risks. She is currently the institutional PI of a breast cancer prevention study of polyphenon E, an active substance of green tea, in women at increased risk for breast cancer. In addition, she is collaborating on a breast cancer prevention study of Lipitor, a cholesterol-lowering drug, in women at increased risk for breast cancer. Dr. Bevers chairs the National Comprehensive Cancer Network’s guideline panels on Breast Cancer Screening and Diagnosis and Breast Cancer Risk Reduction.
A native Texan, Dr. Bevers completed her medical school and residency in Family Practice at The University of Texas Health Science Center at
Research Interests
Breast cancer prevention, screening, diagnosis and survivorship
Clinical Interests
Breast cancer prevention, screening, diagnosis and survivorship
Office Address
The University of Texas MD Anderson Cancer Center
1155 Pressler Street
P.O. Box 301439
Unit Number: 1322
Houston, TX 77230-1439
Phone: (713) 745-8048
1155 Pressler Street
P.O. Box 301439
Unit Number: 1322
Houston, TX 77230-1439
Phone: (713) 745-8048
Education & Training
Degree-Granting Education | |
| 1987 | The University of Texas Health Science Center at San Antonio, San Antonio, TX, MD, Doctor of Medicine |
| 1981 | Texas Woman's University, Denton, TX, BS, Magna Cum Laude, Chemistry, Biology |
Board Certifications
| 7/1990 | American Board of Family Practice |
Experience/Service
Institutional Committee Activities
Member, Duncan Family Institute for Cancer Prevention and Risk Assessment Executive Committee, 2009-present
Member, Personalized Risk Prediction Program Steering Committee, 2009-present
Member, Premalignant Genome Atlas Steering Committee, 2009-present
Member, Comprehensive Cancer Control Strategic Plan Steering Committee, 2008-present
Member, Cancer Survivorship Steering Committee, 2006-present
Co-Chair, Clinical Management Conference for Benign Breast Lesions, 2004-present
Honors and Awards
| 2009-2010 | Who's Who in Medicine and Healthcare |
| 2009 | America's Top Family Doctors |
| 2008 | Who's Who in America |
| 2006-2007 | The Julie and Ben Rogers Award for Excellence in Prevention, The University of Texas M.D. Anderson Cancer Center |
| 2006 | America's Top Family Doctors |
| 2004-2007 | Who's Who in Medicine and Healthcare |
| 1997 | Physician of the Day,, Seventy-fifth Texas Legislature, January 30, |
| 1984-1985 | Notable Women of Texas |
Professional Memberships
| Action Plan on Breast and Cervical Cancer for the State of Texas Member, Steering Committee, 2003 |
| American Cancer Society Co-chair, Leadership Council (Gulf Coast Region), 2010-present Member, Board of Directors (High Plains Division), 2005-2010 |
| American Cancer Society Cancer Action Network Member, Policy Review Group, Transforming Prevention in the American Health Care System, Washington, DC, 2008 |
| American Society of Breast Disease Member, Consensus Committee, 2006-2012 Member, 2005-present |
| American Society of Clinical Oncology Member, 2005-present Member, Reimbursement for Cancer Prevention Services Subcommittee, 2005-2006 |
| National Comprehensive Cancer Network Chair, Breast Cancer Risk Reduction Guideline Panel, 2005-present Chair, Breast Cancer Screening & Diagnostic Guideline Panel, 2003-present |
| National Surgical Adjuvant Breast and Bowel Project Member, Steering Committee, A study to evaluate different decision-making approaches used by women known to be at high risk for breast cancer, 2009-present Member, Board of Directors, 2007-2010 |
| Texas Cancer Plan Member, Executive Steering Committee, 2004 |
| Texas Medical Association Member, Task Force on Prevention, 1997-2000 Member, 1996-present |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S. A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. J Surg Oncol 102(3):220-4, 9/2010. PMID: 20740578. | |
| 2. | Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prev Res (Phila Pa) 3(6):696-706, 6/2010. PMID: 20404000. | |
| 3. | Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM for the WHIMS and CoSTAR Study Groups. Relative Effects of Tamoxifen, Raloxifene, and Conjugated Equine Estrogens on Cognition. Journal of Women's Health 19(3):371-9, 2010. PMCID: PMC2867626. | |
| 4. | Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene. J Clin Oncol 27(31):5144-52, 2009. PMCID: PMC2773473. | |
| 5. | Cyrus-David M, King J, Bevers T, Robinson E. Validity assessment of the Breast Cancer Risk Reduction Health Belief scale. Cancer 115(21):4907-16, 2009. PMCID: PMC2768118. | |
| 6. | Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged </=55 years:. Breast Cancer Res Treat 110(2):357-66, 7/2008. PMID: 17851762. | |
| 7. | Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 5/2008. PMCID: PMC2701362. | |
| 8. | Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295(23):2727-41, 2006. PMID: 16754727. | |
| 9. | Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-62, 11/2005. PMID: 16288118. | |
| 10. | Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122-8, 3/2005. PMID: 15712375. | |
| 11. | Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835-42, 9/2002. PMID: 12231524. | |
| 12. | Singletary, SE, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-Hydroxyphenyl] retinamide. Cancer Epidemiology, Biomarkers and Prevention. 9:1087-1090, 5/2000. | |
Invited Articles | ||
| 1. | Bevers TB. Breast Cancer Prevention: An Update of the STAR Trial. Curr Treat Options Oncol 11(3):66-9, 12/2010. PMID: 21061192. | |
| 2. | Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 8(10):1112-46, 11/2010. PMID: 20971838. | |
| 3. | Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7(10):1060-96, 11/2009. PMID: 19930975. | |
| 4. | Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 58(6):347-371., Nov-Dec, 11/2008. e-Pub 11/2008. PMID: 18981297. | |
| 5. | Bevers TB. Raloxifene: An agent for breast cancer prevention. Expert Rev Obstet Gynecol 3(3):277-85., 2008. | |
| 6. | Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719-24, 9/2007. PMID: 17927929. | |
| 7. | Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 7(16):2301-07, 2006. PMID: 17059385. | |
Editorials | ||
| 1. | Bevers TB. Raloxifene: A new paradigm for breast cancer prevention. Breast Diseases: A YearBook Quarterly 18:24-5, 2007. | |
| 2. | Bevers TB. Breast awareness: a shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042-3, 11/2009. PMID: 19930973. | |
Abstracts | ||
| 1. | K.H, Lu, S. Skates, T.B. Bevers, W. Newland, R. G. Moore, L. Leeds, S. Harris, O.W. Adeyinka, H.A. Fritshe, R.C. Bast. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement) (#5003), 2010. | |
| 2. | L. Shea, T. Bevers, A. Espat, S. Kim, E. Rigby, J. Ward. Cancer risk check offers a personalized feedback based on individual cancer risk. 2010 Cancer Prevention & Research Institute of Texas (CPRIT) (#376), 2010. | |
| 3. | K. D. Crew, P. Brown, H. Greenlee, T. Bevers, B. Arun, C. Hudis, H. L. McArthur, L. Vornik, T. L. Cornelison, D. L. Hershman,. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement) (#TPS142), 2010. | |
| 4. | Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc:995, 2007. PMID: 18694095. | |
| 5. | Barad DH, Bevers TB, Coker LH, Espeland MA, Jaramillo SA, Limacher M, Lane DS, Maki P, Rapp S, Resnick S, Shumaker SA, Stefanick ML. Relative effects of tamoxifen, raloxifene, and estrogen therapy on cognition: Results from the Women's Health Initiative Study of Cognitive Aging (WHISCA) and the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) clinical trials. Society for Gynecologic Investigation, 2007. | |
| 6. | Wickerham DL, Constantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, Bevers T et al. The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol (ASCO Meeting Abstracts) 24:No. 18S(June 20 Supplement) (#LBA5), 2006. | |
Book Chapters | ||
| 1. | Bevers TB. Chapter 86: Clinical Management of the Patient at Increased or High Risk. In: The Breast: comprehensive management of benign and malignant diseases, 4th Edition. Ed(s) Bland KI, Copeland EM. Saunders: Philadelphia, PA, 1381-92, 2009. PMID: 978-1-4160-5221-0. | |
| 2. | Bevers T, Bedrosian I. Chapter 72: Prevention: Prophylactic Mastectomy and Chemoprevention. In: Advanced Therapy for Surgical Oncology. Ed(s) Pollock R, Curley S, Ross M, Perrier N. BC Decker, Inc: Hamilton, Ontario, Canada, 588-96, 2008. | |
| 3. | Bevers T. Breast Self-examination. In: Advanced Therapy of Breast Disease, Second Edition. Ed(s) Singletary SE, Robb GL, Hortobagyi GN. B.C. Decker, Inc.,, 193-201, 2004. | |
| 4. | Bevers T. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: M.D. Anderson Cancer Care Series. Ed(s) Hunt KK, Robb GL, Strom EA, Ueno NT. Springer-Verlag: New York, 21-54, 2001. | |
| 5. | Bevers T. Diagnosis of Palpable Breast Masses. In: Advanced Therapy of Breast Disease. Ed(s) Singletary SE, Robb GL. B. C. Decker, Inc. Hamilton Ontario, 73-82, 2000. | |
Books (edited and written) | ||
| 1. | Vogel VG, Bevers T, Editors. Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers: Sudbury, Mass, 2003. | |
Grant & Contract Support
| Title: | An Integrated Professional Oncology Curriculum for Texas Primary Care Professionals: Improving Care and Enhancing Quality of Life for Breast, Colon and Prostate Cancer Survivors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Principal Investigator: | Lewis Foxhall |
| Duration: | 8/1/2010 - 7/31/2012 |
| Title: | Statistical Methods for Breast Cancer Prevention and Treatment Studies and Therapeutic Response |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Principal Investigator: | Yu Shen |
| Duration: | 6/16/2010 - 4/30/2015 |
| Title: | Blood Test for Breast Cancer Associated Auto Antibodies |
| Funding Source: | Lab Discoveries |
| Role: | Principal Investigator |
| Duration: | 12/1/2009 - 11/30/2011 |
| Title: | The Use of Stimulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer in Women |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Co-Principal Investigator |
| Principal Investigator: | Jennifer Litton |
| Duration: | 6/1/2009 - 10/30/2010 |
| Title: | Phase IB Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Principal Investigator: | Powel Brown |
| Duration: | 9/30/2006 - 9/30/2012 |
| Title: | Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) |
| Funding Source: | NSABP |
| Role: | Principal Investigator |
| Duration: | 2001 - 2008 |
| Title: | Early Detection of Epithelial Ovarian Cancer |
| Funding Source: | National Cancer Institute-DHHS-NIH-P50 |
| Role: | Collaborator |
| Principal Investigator: | Robert Bast |
| Duration: | 9/30/1999 - 8/31/2010 |
| Title: | Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer |
| Funding Source: | NSABP |
| Role: | Principal Investigator |
| Duration: | 1/1/1999 - 5/31/2012 |
Last updated: 3/15/2011
- Global Navigation
- About Us
- Locations
- Calendar
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient and Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children's Cancer Hospital
- Services & Amenities
- Education and Research
- Departments, Programs and Labs
- PeopleFinder
- Research at MD Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alert Information
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates
- Legal and Policy
- Legal Statements
- Site Policies
- Reporting Fraud, Waste & Abuse
© 2010 The University of Texas M. D. Anderson Cancer Center